{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:21:01Z","timestamp":1794648061493,"version":"4.9.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Polypharmacy continues to be a topic of concern among older adults and puts patients at increased risk of potential drug-drug interactions (DDIs) and negative health outcomes. The objective of this study was to assess the prevalence of polypharmacy among older adults with cardiovascular disease (CVD) and to identify severe potential DDIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective chart review was conducted in a tertiary care center over a three-month period where we reviewed home medications of older adults upon hospital admission. Inclusion criteria were age\u2009\u2265\u200965\u2009years, history of CVD, and admission to the cardiology service. Polypharmacy was defined as 5 or more medications taken concomitantly, hyper-polypharmacy was defined as 10 or more medications taken concomitantly, and severe potential DDIs were considered to be those belonging to category D or X using Lexicomp\u00ae Drug Information Handbook. Category D interaction states that modification of therapy should be considered while category X states that the combination should be absolutely avoided.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 404 patients with a mean age of 76.6\u2009\u00b1\u20097.4\u2009years were included. Patients were taking an average of 11.6\u2009\u00b1\u20094.5 medications at home and 385 (95%) received polypharmacy, 278 (69%) received hyper-polypharmacy, and 313 (77.5%) had at least one severe potential DDI. Under category D, the most common potential DDIs were drugs with additive central nervous system (CNS) depressant effect and drugs that increase the risk of QT prolongation. Under category X, the most common potential DDIs were non-selective \u03b2-blockers that may diminish the bronchodilator effect of \u03b2\n                      <jats:sub>2<\/jats:sub>\n                      agonists and drugs with anticholinergic properties that enhance the ulcerogenic effect of oral solid potassium.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Polypharmacy, hyper-polypharmacy, and severe potential DDIs are very common in older adults with CVD. Clinicians should vigilantly review patients\u2019 drug records and adjust therapy accordingly to prevent adverse drug reactions and negative health outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12877-021-02183-0","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T15:03:07Z","timestamp":1617807787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["Polypharmacy and severe potential drug-drug interactions among older adults with cardiovascular disease in the United States"],"prefix":"10.1186","volume":"21","author":[{"given":"Marwan","family":"Sheikh-Taha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Asmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"key":"2183_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.archger.2018.06.018","volume":"78","author":"L Mid\u00e3o","year":"2018","unstructured":"Mid\u00e3o L, Giardini A, Menditto E, Kardas P, Costa E. Polypharmacy prevalence among older adults based on the survey of health, ageing and retirement in Europe. Arch Gerontol Geriatr. 2018;78:213\u201320. https:\/\/doi.org\/10.1016\/j.archger.2018.06.018.","journal-title":"Arch Gerontol Geriatr"},{"key":"2183_CR2","doi-asserted-by":"publisher","first-page":"204209862093374","DOI":"10.1177\/2042098620933741","volume":"11","author":"M Khezrian","year":"2020","unstructured":"Khezrian M, McNeil CJ, Murray AD, Myint PK. An overview of prevalence, determinants and health outcomes of polypharmacy. Therapeutic Adv Drug Safety. 2020;11:2042098620933741.","journal-title":"Therapeutic Adv Drug Safety"},{"issue":"1","key":"2183_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12877-017-0621-2","volume":"17","author":"N Masnoon","year":"2017","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):1.","journal-title":"BMC Geriatr"},{"key":"2183_CR4","volume-title":"Polypharmacy guidance, realistic prescribing","author":"Scottish Government Polypharmacy Model of Care Group","year":"2018","unstructured":"Scottish Government Polypharmacy Model of Care Group. Polypharmacy guidance, realistic prescribing. 3rd ed. Scotland: Scottish Government; 2018.","edition":"3"},{"issue":"4","key":"2183_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1159\/000365328","volume":"61","author":"C G\u00f3mez","year":"2015","unstructured":"G\u00f3mez C, Vega-Quiroga S, Bermejo-Pareja F, Medrano MJ, Louis ED, Benito-Le\u00f3n J. Polypharmacy in the elderly: a marker of increased risk of mortality in a population-based prospective study (NEDICES). Gerontology. 2015;61(4):301\u20139. https:\/\/doi.org\/10.1159\/000365328.","journal-title":"Gerontology."},{"issue":"6","key":"2183_CR6","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.amjopharm.2011.10.004","volume":"9","author":"LE Hines","year":"2011","unstructured":"Hines LE, Murphy JE. Potentially harmful drug\u2013drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011;9(6):364\u201377. https:\/\/doi.org\/10.1016\/j.amjopharm.2011.10.004.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"4","key":"2183_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.cger.2009.07.007","volume":"25","author":"A Yazdanyar","year":"2009","unstructured":"Yazdanyar A, Newman AB. The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. Clin Geriatr Med. 2009;25(4):563\u201377. https:\/\/doi.org\/10.1016\/j.cger.2009.07.007.","journal-title":"Clin Geriatr Med"},{"issue":"1","key":"2183_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrcardio.2010.162","volume":"8","author":"JL Fleg","year":"2011","unstructured":"Fleg JL, Aronow WS, Frishman WH. Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol. 2011;8(1):13\u201328. https:\/\/doi.org\/10.1038\/nrcardio.2010.162.","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"2183_CR9","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1080\/03007995.2018.1447453","volume":"34","author":"WK Kabbara","year":"2018","unstructured":"Kabbara WK, Dimassi H, Sheikh-Taha M. Patterns of pain medication use in older individuals with cardiovascular disease. Curr Med Res Opin. 2018;34(5):931\u20134. https:\/\/doi.org\/10.1080\/03007995.2018.1447453.","journal-title":"Curr Med Res Opin"},{"key":"2183_CR10","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association AP, American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). American Psychiatric Pub. 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"2183_CR11","volume-title":"Lexi-Drugs\u00ae","author":"Lexicomp, Inc.","year":"2019","unstructured":"Lexicomp, Inc. Lexi-Drugs\u00ae. Hudson: Lexicomp, Inc.; 2019. https:\/\/www.wolterskluwer.com\/en\/solutions\/lexicomp"},{"issue":"2","key":"2183_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00228-014-1786-7","volume":"71","author":"T Roblek","year":"2015","unstructured":"Roblek T, Vaupotic T, Mrhar A, Lainscak M. Drug-drug interaction software in clinical practice: a systematic review. Eur J Clin Pharmacol. 2015;71(2):131\u201342. https:\/\/doi.org\/10.1007\/s00228-014-1786-7.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"2183_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4103\/2279-042X.192461","volume":"5","author":"R Kheshti","year":"2016","unstructured":"Kheshti R, Aalipour M, Namazi S. A comparison of five common drug\u2013drug interaction software programs regarding accuracy and comprehensiveness. J Res Pharmacy Pract. 2016;5(4):257\u201363. https:\/\/doi.org\/10.4103\/2279-042X.192461.","journal-title":"J Res Pharmacy Pract"},{"key":"2183_CR14","doi-asserted-by":"publisher","unstructured":"Ward BW, Schiller JS, Goodman RA. Peer reviewed: multiple chronic conditions among us adults: a 2012 update. Prev Chronic Dis. 2014;11. https:\/\/doi.org\/10.5888\/pcd11.130389.","DOI":"10.5888\/pcd11.130389"},{"key":"2183_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2147\/CLEP.S153458","volume":"10","author":"L Morin","year":"2018","unstructured":"Morin L, Johnell K, Laroche ML, Fastbom J, Wastesson JW. The epidemiology of polypharmacy in older adults: register-based prospective cohort study. Clin Epidemiol. 2018;10:289\u201398. https:\/\/doi.org\/10.2147\/CLEP.S153458.","journal-title":"Clin Epidemiol"},{"issue":"6","key":"2183_CR16","doi-asserted-by":"publisher","first-page":"e98043","DOI":"10.1371\/journal.pone.0098043","volume":"9","author":"HA Kim","year":"2014","unstructured":"Kim HA, Shin JY, Kim MH, Park BJ. Prevalence and predictors of polypharmacy among Korean elderly. PLoS One. 2014;9(6):e98043. https:\/\/doi.org\/10.1371\/journal.pone.0098043.","journal-title":"PLoS One"},{"issue":"6","key":"2183_CR17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2165\/00002512-200926060-00006","volume":"26","author":"J Jyrkk\u00e4","year":"2009","unstructured":"Jyrkk\u00e4 J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Patterns of drug use and factors associated with polypharmacy and excessive polypharmacy in elderly persons. Drugs Aging. 2009;26(6):493\u2013503. https:\/\/doi.org\/10.2165\/00002512-200926060-00006.","journal-title":"Drugs Aging"},{"issue":"1","key":"2183_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/fampra\/cml067","volume":"24","author":"U Junius-Walker","year":"2007","unstructured":"Junius-Walker U, Theile G, Hummers-Pradier E. Prevalence and predictors of polypharmacy among older primary care patients in Germany. Fam Pract. 2007;24(1):14\u20139. https:\/\/doi.org\/10.1093\/fampra\/cml067.","journal-title":"Fam Pract"},{"issue":"3","key":"2183_CR19","doi-asserted-by":"publisher","first-page":"e0173466","DOI":"10.1371\/journal.pone.0173466","volume":"12","author":"LM Lim","year":"2017","unstructured":"Lim LM, McStea M, Chung WW, Nor Azmi N, Abdul Aziz SA, Alwi S, et al. Prevalence, risk factors and health outcomes associated with polypharmacy among urban community-dwelling older adults in multi-ethnic Malaysia. PLoS One. 2017;12(3):e0173466. https:\/\/doi.org\/10.1371\/journal.pone.0173466.","journal-title":"PLoS One"},{"issue":"1","key":"2183_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-018-1078-7","volume":"16","author":"J Burt","year":"2018","unstructured":"Burt J, Elmore N, Campbell SM, Rodgers S, Avery AJ, Payne RA. Developing a measure of polypharmacy appropriateness in primary care: systematic review and expert consensus study. BMC Med. 2018;16(1):1\u20135.","journal-title":"BMC Med"},{"issue":"4","key":"2183_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2710.2009.01021.x","volume":"34","author":"A Nobili","year":"2009","unstructured":"Nobili A, Pasina L, Tettamanti M, Lucca U, Riva EM, Marzona I, et al. Potentially severe drug interactions in elderly outpatients: results of an observational study of an administrative prescription database. J Clin Pharm Ther. 2009;34(4):377\u201386. https:\/\/doi.org\/10.1111\/j.1365-2710.2009.01021.x.","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"2183_CR22","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jgs.15767","volume":"67","author":"DM Fick","year":"2019","unstructured":"2019 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS beers criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674\u201394.","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"2183_CR23","first-page":"473","volume":"42","author":"M Li","year":"2017","unstructured":"Li M, Ramos LG. Drug-induced QT prolongation and torsades de pointes. Pharmacy Therapeutics. 2017;42(7):473\u20137.","journal-title":"Pharmacy Therapeutics"},{"issue":"5","key":"2183_CR24","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2165\/00003088-198409050-00002","volume":"9","author":"PG Welling","year":"1984","unstructured":"Welling PG. Interactions affecting drug absorption. Clin Pharmacokinet. 1984;9(5):404\u201334. https:\/\/doi.org\/10.2165\/00003088-198409050-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2183_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12916-017-0781-0","volume":"15","author":"DR Morales","year":"2017","unstructured":"Morales DR, Lipworth BJ, Donnan PT, Jackson C, Guthrie B. Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study. BMC Med. 2017;15(1):18. https:\/\/doi.org\/10.1186\/s12916-017-0781-0.","journal-title":"BMC Med"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-021-02183-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12877-021-02183-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-021-02183-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T15:06:13Z","timestamp":1617807973000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgeriatr.biomedcentral.com\/articles\/10.1186\/s12877-021-02183-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2183"],"URL":"https:\/\/doi.org\/10.1186\/s12877-021-02183-0","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"16 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was obtained from Huntsville Hospital\u2019s Institutional Review Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"233"}}